You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al

Citation Tools

Article menu

Download PDFPDF

Letter
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Immisch L, Papafotiou G, Popp O, et al
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chheda et al
Journal for ImmunoTherapy of Cancer 2023;11:e006784. doi: 10.1136/jitc-2023-006784